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Abstract Two 54-year-old women developed abdominal
cramps and vaginal hemorrhage as a result of endometrial
hyperplasia during treatment with a hop-containing phy-
totherapeutic product (MenoCool) for post-menopausal
complaints. The women used the hop-containing phy-
totherapeutic product (418 mg of hop per tablet) twice
daily (1 and 0.5 tablets by both patient A and B). Patient A
developed abdominal cramps and vaginal hemorrhage after
2 months of use. After gynecological examination, she was
diagnosed with endometrial hyperplasia. The patient was
treated with a curettage. The hop-containing phytothera-
peutic product was discontinued, and the patient recovered.
Patient B developed abdominal pain/cramps and vaginal
hemorrhage after 5 months of use. A cervix smear, internal
examination, and ultrasound were performed. Due to the
thickness of the endometrium, a pipelle endometrial biopsy
was performed. Results showed no indication for cervix
cancer. The use of MenoCool was ceased; follow-up
information received from the patient shortly thereafter
indicated that she had almost entirely recovered from the
abdominal pain/cramps and vaginal hemorrhage. Hop
(Humulus lupulus) has phytoestrogenic properties that may
be the cause of endometrial hyperplasia and subsequent
vaginal hemorrhage. A Naranjo assessment score of 5 was
obtained for both cases, indicating a probable relationship
between the patient’s endometrial proliferation and subse-
quent vaginal hemorrhage and their use of the suspect drug.
Key Points
Many women use natural health products for relief of
menopausal symptoms and perceive these products
as safe.
Phytotherapeutic products for menopausal
complaints can contain plants with phytoestrogenic
properties.
The use of phytoestrogens can be related to
endometrial hyperplasia and subsequent vaginal
hemorrhage.
Introduction
Several treatment options exist for the treatment of
menopausal symptoms in women. The use of hormone-
replacement therapy (HRT) has decreased substantially
after publication of the Women’s Health Initiative (WHI)
trial in 2002 [1–3]. Many post-menopausal women often
perceive phytoestrogens in food supplements as a safer
alternative than HRT [2], because these products are
‘natural’. The use of these products is widespread [4].
Phytoestrogens represent a diverse group of non-ster-
oidal natural products that have some estrogenic effects
and are often marketed as food supplements [2]. Phytoe-
strogens are secondary metabolites that can mimic or
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modulate the actions of endogenous estrogens, usually by
binding to estrogen receptors (ERs) [2]. The three major
classes of phytoestrogens found in typical human diets are
isoflavones (such as genistein and daidzein), which are
concentrated in soybeans and soy products, but are also
found in other legumes; lignans, which are distributed in
seeds, whole grains, berries, fruit, vegetables, and nuts; and
coumestans, which are found in broccoli and sprouts [2].
The flavonoid substance 8-prenylnaringenin (hopein) in
hop also has phytoestrogenic properties. Of all phytoe-
strogens, 8-prenylnaringenin has the strongest ER activity
[5, 6].
In the period from November 2011 to April 2015, the
Netherlands Pharmacovigilance Centre Lareb received
seven reports of vaginal hemorrhage caused by endometrial
hyperplasia related to the use of the same hop-containing
phytotherapeutic product (MenoCool). The first three
cases were reported by the same gynecologist and pub-
lished in a Dutch medical journal in 2012 [7]. Since then,
Lareb has received four more cases concerning the same
association: two from gynecologists from different hospi-
tals in the Netherlands and two directly from a patient.
These last reports, received directly from patients, are
described below.
Case Reports
Patient A, a 54-year-old woman (weight 79 kg, height 177
cm, body mass index [BMI] 25.2 kg/m2) had been using the
phytotherapeutic product MenoCool (two times daily;
morning one tablet, evening 0.5 tablet per oral adminis-
tration) for the indication hot flushes and vaginal dryness
due to the menopause. She had bought the product online
through the manufacturer’s website (http://www.menocool.
nl). The patient had not previously used the suspected drug.
At that time, she had not menstruated for 2 years but had
experienced hot flushes for approximately 4 years. The
patient had never had an abnormal cervix smear, except a
Pap III result 20 years previously. However, a repeated
smear test showed no abnormalities. She had no medical
history of vaginal bleeding, endometrial hyperplasia,
endometrial polyps, or uterine leiomyomas. Her concomi-
tant medication consisted of fexofenadine 120 mg once
daily and mometasone 50 lg/dosage nasal inhalation spray,
both since 2005. The patient started using MenoCool in
April 2014. After using MenoCool for 2 months, the
patient started to experience abdominal cramps and vaginal
hemorrhage. These complaints were diagnosed by a
gynecologist as related to a high proliferation of the
endometrium. The patient was hospitalized for a day and
underwent a curettage. After the curettage, the patient went
for a follow-up appointment to her gynecologist and a
significant increase in the endometrium was found again.
The patient was treated with a course of norethisterone.
Norethisterone has been effective in the treatment of dys-
functional uterine bleeding in patients with a proliferative
or hyperplastic endometrium [8] and, as expected, the
patient had a heavy withdrawal bleeding following with-
drawal of norethisterone that lasted for several days. The
following control appointment showed proliferation of the
endometrium again but still within the normal range; this
time no action was deemed necessary. According to the
patient, the gynecologist in the hospital had no explanation
for the rapid and extreme growth of the endometrium. The
patient ceased the use of the phytotherapeutic product in
September 2014 and had fully recovered by the time fol-
low-up information was received by the pharmacovigilance
center in February 2015. After a consultation in a women’s
health clinic, the patient was told by another gynecologist
that she should not use drugs against hot flushes containing
phytoestrogens to prevent a repeat of her complaints. Her
endometrium was diagnosed at this clinic as thick but
within the normal range, and there has been no hyperplasia
of the endometrium or vaginal bleeding since.
Patient B, a 54-year-old woman (weight 70 kg, height
176 cm, BMI 22.6 kg/m2), had been using MenoCool (1.5
tablets daily) for the indication hot flushes due to the
menopause. She also bought the product online, through
the same website as patient A. The patient had not previ-
ously used the suspected drug. She had not menstruated for
5 years. Her concomitant medication consisted of another
supplement from the same manufacturer: MenoCool Extra
oral lyophilisate (2 tablets daily) containing a non-estro-
genic flavone extract 22 mg, vitamin D3 5 lg, biotine 25
lg. In addition, she had been using alendronic acid 70 mg
once weekly since 2012. The patient started using
MenoCool in October 2014. The MenoCool Extra oral
lyophilisate was added shortly after the start of
MenoCool, following the advice of the manufacturer,
because the patient experienced abdominal pain/cramps.
After 5 months using this combination, the patient expe-
rienced vaginal hemorrhage. She was referred by her
general practitioner to a gynecologist. A cervix smear,
internal examination, and ultrasound were performed. Due
to the thickness of the endometrium, a pipelle endometrial
biopsy was performed. Results showed no indication for
cervix cancer. The use of MenoCool was ceased on 2
April 2015; on 13 April 2015 follow-up information
received from the patient indicated that she had almost
entirely recovered from the abdominal pain/cramps and
vaginal hemorrhage.
According to the product’s manufacturer (Standby Vital
BV, based in the Netherlands), the phytotherapeutic pro-
duct MenoCool consists of a combination of three kinds
of hops (Humulus lupulus) selected for their flavonoid
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content, a natural isoflavones complex, buckwheat
(Fagopyrum esculentum), black oat (Avena sativa), malt
(Semen hordei vulgaris germinatum), barley (Hordeum
vulgare), rye (Secale cereale), wheat (Triticum aestivum),
corn (Zea mays), and dietary fiber. Exact ingredients of the
product, as specified by the manufacturer, are given in
Table 1.
Discussion
Vaginal bleeding is not uncommon in post-menopausal
women and occurs in approximately 4–11 % of women
who have reached menopause [9, 10]. The incidence of
bleeding appears to correlate with time since menopause,
with the likelihood of bleeding decreasing over time [10].
Recurrence of bleeding is very common in the time
immediately after menopause, being the 12 months of
amenorrhea after what is currently defined as the final
menstrual period, declining to low frequencies more than 3
years after the final menstrual period [10]. The differential
diagnosis of bleeding in post-menopausal women can
include endometrial cancer, polyps, leiomyomata uteri
(fibroids), and infection, among others. Endometrial
hyperplasia may manifest clinically as uterine bleeding;
however, since post-menopausal women should be estro-
gen deficient, endometrial hyperplasia at this time is
abnormal and should be further investigated [9]. Post-
menopausal hormone therapy can be a cause of endome-
trial hyperplasia and subsequent post-menopausal bleeding
[11]. Soy and other phytoestrogens in large doses may be
associated with stimulation of the endometrial lining, as
has also been described by the Netherlands Pharmacovig-
ilance Centre Lareb in a previous case series [7]. A ran-
domized trial of 376 post-menopausal women who
received soy versus placebo over a 5-year period showed
that the occurrence of endometrial hyperplasia was sig-
nificantly higher in the group receiving soy (3.37 vs. 0 %)
[12].
In addition to soy, other plants have phytoestrogen
properties. Hops are the female flowers (seed cones, stro-
biles) of the hop species Humulus lupulus L. The principal
estrogen from hops is the 1:1 racemate, (±)-8-prenyl-
naringenin ‘8PN’, also called hopein [13]. This is one of
the most potent in vitro estrogenic substance known from
the plant kingdom [5, 6, 13], with an estrogenic activity
in vitro greater than that of other phytoestrogens such as
coumestrol, genistein, and daidzein [14]. Nowadays, hops
are used primarily for their bitter and aromatic properties in
the manufacture of beer and are cultivated by the brewing
industry. The content of 8-prenylnaringenine in beer varies
widely. Most beer does not contain 8-prenylnaringenin in
detectable quantities; the highest concentration found being
19.8 lg L-1 [15]. Although the percentage of hop in the
product used in this case report is known (41.40 %), the
8-prenylnaringenin amount is not.
In addition to hop, the product also contains other plants
that have phytoestrogenic activities. The plant lignans
secoisolariciresinol (SEC) and matairesinol (MAT), which
can be found in cereals, are converted to the metabolites
enterodiol (ED) and enterolactone (EL), known as the
mammalian lignans, in the gastrointestinal tract [16]. These
compounds are bioactive as phytoestrogens because of
their structural and functional similarity to 17b-estradiol
[17]. In vitro, mammalian lignans may have both estro-
genic and anti-estrogenic properties [16]. For cereals like
oats (A. sativa), barley (H. vulgare), and rye (S. cereale),
the presence of lignans with phytoestrogenic properties has
been described [16–18]. Malt is germinated cereal grains
that have been dried in a process known as ‘malting’.
Various cereals are malted, though barley is the most
common. Isoflavones are also found in cereals [17] and are
an additional ingredient in this product. The exact nature of
the ‘natural isoflavones complex’ described on the pack-
aging of the product is unknown. Dietary flavonoids are
also known for their antiplatelet activity, although the
specific mechanisms by which this inhibition occurs has
not been fully established. Inhibition of the platelet func-
tion through binding to the thromboxane A2 receptor has
been described [19]. It is possible that all the ingredients
with phytoestrogenic properties in the product could have
had an additional effect to each other in causing the
endometrial proliferation and subsequent vaginal hemor-
rhage. Estrogenic activity of the product was found in an
ER assay with 17-b-estradiol as a comparator by the
company PhytoGeniX, which is a spin off contract research
organization originating from the University of Utrecht
(Department of Medicinal Chemistry, Faculty of
Table 1 Ingredients of the product MenoCool as described by the
manufacturer (tablet weight 1010 mg)
Ingredients Percentage
Hop (Humulus lupulus) 41.40
Dietary fiber 9.90
Buckwheat (Fagopyrum esculentum) 8.48
Black oats (Avena sativa) 8.48
Malt (Semen hordei vulgaris germinatum) 8.48
Rye (Secale cereale) 4.24
Barley (Hordeum vulgare) 4.24
Wheat (Triticum aestivum) 4.24
Corn (Zea mays) 4.24
Silicon (as an excipient for hair and nails) 4.10
Natural isoflavones complex 1.80
Vegetable magnesium stearate 0.40
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Pharmacy) in the Netherlands [20]. The following is stated
on the products’ website (http://www.menocool.nl): ‘‘Only
in the event that your uterus is removed, the starting dose is
suitable for use indefinitely’’.
In Europe, products marketed as dietary supplements are
loosely regulated as compared with medicines. This phy-
totherapeutic product is not officially registered through the
Dutch Medicines Evaluation Board, but is sold as a food
supplement, which falls under the jurisdiction of the Dutch
Netherlands Food and Consumer Product Safety Authority
(NVWA). The Commodities Act requires that these prod-
ucts are safe, but no mandatory safety testing takes place
before they come on the market. Pharmacovigilance sys-
tems for registered drugs are well-defined. For food sup-
plements, although they can contain pharmacologically
active ingredients, such systems (‘nutrivigilance’) are less
developed [21]. For pharmacovigilance, engaging con-
sumer reports can be especially helpful in the recognition
of ‘blind spots’ such as adverse reactions caused by
(adulterated) herbal product and counterfeit medicines [22,
23]. In addition, awareness among healthcare professionals
that patients can use herbal drugs or other products, bought
without a prescription, is important.
With products bought over the internet, there is always a
chance that the product is adulterated with conventional
medicines. However, we deem it unlikely that this company
has adulterated the herbal product with Western medicines.
The product itself is compounded by DuSart Pharma (Kat-
wijk, the Netherlands). For the department ‘dry formula-
tions’ (tablets and capsules) DuSart Pharma adheres to the
Pharma GMP regimen of nutritional supplements in accor-
dance with a quality guideline issued by the European
Federation of Associations of Health Product Manufactures
(EHPM). DuSart Pharma complies with the Hazard Analysis
and Critical Control Points (HACCP) requirements [24, 25].
Also, the owner of the company selling the product, among
other herbal products such as a natural breast size enhancer,
has been featured in both national and local newspapers in
the Netherlands [26–28], and a skeptical article about their
products was published in a Dutch medical journal [29]. A
complaint about MenoCool was also filed with the Dutch
Advertising Code Committee. This was upheld and the
manufacturer had to remove some of the health claims from
the product’s website [28].
A limitation of this case description is that some of the
characteristics of the herbal product, as recommended in
the CONSORT (Consolidated Standards of Reporting
Trials) statement [30], are unknown to the authors. Since
Lareb received spontaneous reports on the MenoCool
tablets and did not investigate the products in a trial setting,
the authors have no information on what parts of the plants
were used in this product. From a Dutch newspaper article,
we know some limited details on the production process by
DuSart Pharma for products they made for Standby Vital
BV. The described production process, at the time of
publication of the article, was rather simple: plant materials
were ground and the created thick paste was used to press
tablets [27]. The manufacturer of the product declares that
it consists of 100 % plant materials. Based on a visual
inspection of the tablets, we presume that the tablets indeed
consist of pressed plant materials. However, the Nether-
lands Pharmacovigilance Centre Lareb has not performed
any qualitative testing on the product.
Conclusion
Based on the described cases and five earlier case reports to
the Dutch pharmacovigilance center, we suggest a causal
relation between vaginal bleeding due to endometrial
proliferation after menopause associated with the use of
this hop-containing product. A Naranjo assessment score of
5 was obtained for both case A and B, indicating a probable
relationship between the vaginal hemorrhage and
endometrial proliferation and their use of the suspect drug.
Phytoestrogenic products for relief of menopausal symp-
toms are available as over-the-counter preparations, and
consumers often mistakenly believe that they do not cause
adverse drug reactions. In the differential diagnosis, it is
important to be aware that the use of a dietary supplement
or an herbal drug with phytoestrogenic properties may be a
possible cause of post-menopausal bleeding.
Acknowledgments Florence van Hunsel, Sonja van de Koppel, and
Eugene van Puijenbroek declare that they have no conflicts of
interest.
No financial support was received for the conduct of this study or
preparation of this manuscript.
Written informed consent was obtained from each of the patients
for the publication of these case reports. Copies of the consents may
be requested for review from the corresponding author.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooper-
berg C, Stefanick ML, et al. Risks and benefits of estrogen plus
progestin in healthy postmenopausal women: principal results
From the Women’s Health Initiative randomized controlled trial.
JAMA. 2002;288(3):321–33.
2. Poluzzi E, Piccinni C, Raschi E, Rampa A, Recanatini M, De PF.
Phytoestrogens in postmenopause: the state of the art from a
14 Page 4 of 5 F. van Hunsel et al.
chemical, pharmacological and regulatory perspective. Curr Med
Chem. 2014;21(4):417–36.
3. Nettekoven M. Menopauze vaker met hormonen te lijf,
Ondergebruik is onnodig. Pharm Weekbld. 2012;147(5):14–17.
4. Kurzer MS. Phytoestrogen supplement use by women. J Nutr.
2003;133(6):1983S–6S.
5. Milligan S, Kalita J, Pocock V, Heyerick A, De CL, Rong H,
et al. Oestrogenic activity of the hop phyto-oestrogen, 8-prenyl-
naringenin. Reproduction. 2002;123(2):235–42.
6. Overk CR, Yao P, Chadwick LR, Nikolic D, Sun Y, Cuendet
MA, et al. Comparison of the in vitro estrogenic activities of
compounds from hops (Humulus lupulus) and red clover (Tri-
folium pratense). J Agric Food Chem. 2005;53(16):6246–53.
7. van Hunsel FP, Kampschoer P. Postmenopausal bleeding and dietary
supplements: a possible causal relationship with hop- and soy-con-
taining preparations. Ned Tijdschr Geneeskd. 2012;156(41):A5095.
8. Micromedex 1.0 (Healthcare Series). Detailed evidence-based
information (DRUGDEX) norethisterone. http://www.
micromedexsolutions.com/. 2015 [cited 19 Mar 2015].




7E33&sectionRank=1&anchor=H15#H15. 2015 [cited 1 Feb
2015]. Available from: http://www.uptodate.com.
10. Astrup K, Olivarius NF. Frequency of spontaneously occurring
postmenopausal bleeding in the general population. Acta Obstet
Gynecol Scand. 2004;83(2):203–7.
11. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone
therapy in postmenopausal women and risk of endometrial
hyperplasia. Cochrane Database Syst Rev. 2012;8:CD000402.
12. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo
GC. Endometrial effects of long-term treatment with phytoe-
strogens: a randomized, double-blind, placebo-controlled study.
Fertil Steril. 2004;82(1):145–8.
13. Chadwick LR, Pauli GF, Farnsworth NR. The pharmacognosy of
Humulus lupulus L. (hops) with an emphasis on estrogenic
properties. Phytomedicine. 2006;13(1–2):119–31.
14. Milligan S, Kalita J, Pocock V, Heyerick A, De CL, Rong H,
et al. Oestrogenic activity of the hop phyto-oestrogen, 8-prenyl-
naringenin. Reproduction. 2002;123(2):235–42.
15. Tekel’ J, De KD, Rong H, Daeseleire E, Van PC. Determination
of the hop-derived phytoestrogen, 8-prenylnaringenin, in beer by
gas chromatography/mass spectrometry. J Agric Food Chem.
1999;47(12):5059–63.
16. Meagher LP, Beecher GR. Assessment of data on the lignan
content of foods. J Food Compost Anal. 2000;13(6):935–46.
17. Kuhnle GG, Dell’aquila C, Aspinall SM, Runswick SA, Mulligan
AA, Bingham SA. Phytoestrogen content of cereals and cereal-
based foods consumed in the UK. Nutr Cancer.
2009;61(3):302–9.
18. Ososki AL, Kennelly EJ. Phytoestrogens: a review of the present
state of research. Phytother Res. 2003;17(8):845–69.
19. Guerrero JA, Lozano ML, Castillo J, Benavente-Garcia O,
Vicente V, Rivera J. Flavonoids inhibit platelet function through
binding to the thromboxane A2 receptor. J Thromb Haemost.
2005;3(2):369–76.
20. PhytoGeniX. PhytoGeniX projects—Menocool. http://www.
phytogenixnl/the-company/phytogenix-projects/. 2014 [cited 8
Jan 2015]. Available from: http://www.phytogenix.nl.
21. Schmitz SM, Lopez HL, MacKay D. Nutravigilance: principles
and practices to enhance adverse event reporting in the dietary
supplement and natural products industry. Int J Food Sci Nutr.
2014;65(2):129–34.
22. Walji R, Boon H, Barnes J, Austin Z, Welsh S, Baker GR.
Consumers of natural health products: natural-born pharma-
covigilantes? BMC Complement Altern Med. 2010;10:8.
23. van Hunsel F, Harmark L, Pal S, Olsson S, van Grootheest K.
Experiences with adverse drug reaction reporting by patients: an
11-country survey. Drug Saf. 2012;35(1):45–60.
24. DuSart Pharma. DuSart Pharma website. http://www.
dusartpharma.com/Default?lang=EN. 2015 [cited 28 July 2015].
Available from: http://www.dusartpharma.com.
25. USA Food and Drug Administration (FDA). Hazard Analysis &
Critical Control Points (HACCP). http://www.fda.gov/Food/
GuidanceRegulation/HACCP/. 2015 [cited 28 Sept 2015].
Available from: http://www.fda.gov/.
26. Scholtens B. Studie naar borstvergrotende pil. Algemeen Dagblad
(AD). 6 Dec 2003. Sect. Geld[producten.
27. van Calmthout M. De Wonderhop. De Volkskrant. 6 Jan 2001.
Sect. Archive.
28. Unknown journalist. Online gevecht over voedingssupplement.
Dagblad de Limburger. 8 Nov 2012. Sect. Economy.
29. Kievits F, Adriaanse MT. Wonderbaarlijke borstvergroting. Ned
Tijdschr Geneeskd. 2003;147:2598–9.
30. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier
C. Reporting randomized, controlled trials of herbal interven-
tions: an elaborated CONSORT statement. Ann Intern Med.
2006;144(5):364–7.
Phytotherapeutics and Post-Menopausal Vaginal Hemorrhage Page 5 of 5 14
